A cycle involving HMGB1, IFN-γ and dendritic cells plays a putative role in anti-tumor immunity
Authors:
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Cellular Immunology
- Vol. 343, 103850
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Henan Province (201501004)
- National Natural Science Foundation of China (81502689)
This publication has 30 references indexed in Scilit:
- Association of Pro-Inflammatory Cytokines and Iron Regulatory Protein 2 (IRP2) with Leishmania Burden in Canine Visceral LeishmaniasisPLOS ONE, 2013
- Immunosuppressive Mechanisms of Regulatory Dendritic Cells in CancerCancer Microenvironment, 2013
- Immunogenic cell death and DAMPs in cancer therapyNature Reviews Cancer, 2012
- Cancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant MesotheliomaCancer Research, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Marginating Dendritic Cells of the Tumor Microenvironment Cross-Present Tumor Antigens and Stably Engage Tumor-Specific T CellsCancer Cell, 2012
- Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1–Her2341–456 fusion proteinCellular & Molecular Immunology, 2011
- High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytesImmunobiology, 2009
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenalNature Reviews Immunology, 2005